Loading...Loading...Thursday, Genentech, a unit of Roche Holdings AG RHHBY, released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo. The weight loss achieved with CT-388 was clinically meaningful, with a mean placebo-adjusted weight loss of 18.8% (p-value < 0.001). At week 24, 100% of CT-388 treated participants achieved a weight loss of over 5%, 85% achieved over 10%, 70% achieved over 15%, and 45% achieved over 20%. The treatment was well tolerated, with mild to moderate gastrointestinal-related adverse events being the most common, consistent with the incretin class of medicines that CT-388 belongs to. All participants with a pre-diabetes status at baseline became normoglycemic after 24 weeks of CT-388 treatment, whereas the glycemic status of participants treated with placebo remained largely unchanged during this period.CT-388 belongs to the class of incretin-based medicines that aim to regulate blood sugar and reduce appetite. It selectively targets and activates two specific receptors in the body, GLP-1 and GIP, which integrate nutrient-derived signals to control food intake, energy absorption and assimilation.An additional cohort from the ongoing placebo-controlled Phase 1b trial of CT-388 will evaluate obese patients (BMI>30 kg/m2) with type 2 diabetes over a 12-week treatment duration. Roche expects data from this additional cohort in the second half of 2024.In December, Roche agreed to acquire a privately held obesity company, Carmot Therapeutics, for $2.7 billion in cash.

正在加载。。。正在加载。。。周四，罗氏控股公司（RocheHoldings AG RHHBY）旗下的基因泰克（Genentech）发布了CT-388的1b期临床试验结果，CT-388是一种双重GLP-1/GIP受体激动剂，正在开发用于治疗肥胖和2型糖尿病。该研究发现，与安慰剂相比，在24周内每周一次皮下注射CT-388可导致肥胖健康成年人的体重显着减轻。CT-388实现的体重减轻具有临床意义，平均安慰剂调整体重减轻18.8%（p值<0.001）。在第24周，100%接受CT-388治疗的参与者体重减轻超过5%，85%达到10%以上，70%达到15%以上，45%达到20%以上。该治疗耐受性良好，轻度至中度胃肠道相关不良事件是最常见的，与CT-388所属的肠降血糖素类药物一致。所有基线糖尿病前期状态的参与者在CT-388治疗24周后血糖正常，而在此期间用安慰剂治疗的参与者的血糖状态基本保持不变。CT-388属于肠降血糖素类药物，旨在调节血糖和减少食欲。它选择性地靶向并激活体内的两种特定受体GLP-1和GIP，它们整合营养衍生的信号以控制食物摄入，能量吸收和同化。正在进行的安慰剂对照的CT-388 1b期试验的另一个队列将在12周的治疗期间评估肥胖的2型糖尿病患者（BMI>30 kg/m2）。罗氏预计2024年下半年将获得这一额外队列的数据。12月，罗氏同意以27亿美元现金收购一家私营肥胖公司Carmot Therapeutics。

Additionally, Carmot’s equ.

此外，卡莫特的equ。